El-Mekkawy Sahar, Meselhy Meselhy Ragab, Abdel-Hafez Atef Abdel-Monem, Nakamura Norio, Hattori Masao, Kawahata Takuya, Otake Toru
Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, Sugitani, Japan.
Chem Pharm Bull (Tokyo). 2002 Apr;50(4):523-9. doi: 10.1248/cpb.50.523.
Forty-eight derivatives of phorbol (9) and isophorbol (14) were evaluated for their inhibition of human immunodeficiency virus (HIV)-1 induced cytopathic effects (CPE) on MT-4 cells, as well as their activation of protein kinase C (PKC), as indices of anti-HIV-1 and tumor promoting activities, respectively. Of these compounds, the most potent inhibition of CPE was observed in 12-O-tetradecanoylphorbol 13-acetate (8) and 12-O-acetylphorbol 13-decanoate (6). The former also showed the strongest PKC activation activity, while the latter showed no activity at 10 ng/ml. Both activities were generally observed in those phorbol derivatives with an A/B trans configuration, but not in the isophorbol derivatives with an A/B cis configuration. Acetylation of 20-OH in the phorbol derivatives significantly reduced the inhibition of CPE, as shown in 12-O-, 20-O-diacetylphorbol 13-decanoate (6a) (IC100=15.6 microg/ml) vs. compound 6 (IC100=0.0076 microg/ml), and 12-O-tetradecanoylphorbol 13,20-diacetate (8a) (IC100=15.6 microg/ml) vs. 12-O-tetradecanoylphorbol 13-acetate (8) (IC100=0.00048 microg/ml), except in the case of 12-O-decanoylphorbol 13-(2-methylbutyrate) (4) and phorbol 12,13-diacetate (9c). The reduction of a carbonyl group at C-3 abruptly reduced the inhibition of CPE, as observed in 3beta-hydroxyphorbol 12,13,20-triacetate (9f) (IC100=500 microg/ml) vs. phorbol 12,13,20-triacetate (9d) (IC100=62.5 microg/ml). Although 8 was equipotent in the inhibition of CPE, and activation of PKC, both activities were abruptly decreased by the acetylation of 20-OH and methylation of 4-OH [as in 8a and 4-O-methyl-12-O-tetradecanoylphorbol 13,20-diacetate (8b), respectively]. On the other hand, its positional isomer (12-O-acetylphorbol 13-tetradecanoate (8c) showed neither activities. The removal of a long acyl group in 8 led to a substantial loss of both activities, as shown in phorbol 13-acetate (9b). Of the 12-O-acetyl-13-O-acylphorbol derivatives, the highest inhibition of CPE was observed in 6, which has a dodecanoyl residue at C-13. Both an increase and decrease in the number of fatty acid carbon chains resulted in significant reduction of the inhibition of CPE.
对48种佛波醇(9)和异佛波醇(14)衍生物进行了评估,分别以它们对人免疫缺陷病毒(HIV)-1诱导的MT-4细胞病变效应(CPE)的抑制作用以及对蛋白激酶C(PKC)的激活作用作为抗HIV-1活性和促肿瘤活性的指标。在这些化合物中,12-O-十四烷酰佛波醇13-乙酸酯(8)和12-O-乙酰佛波醇13-癸酸酯(6)对CPE的抑制作用最强。前者还表现出最强的PKC激活活性,而后者在10 ng/ml时无活性。一般来说,这两种活性在具有A/B反式构型的佛波醇衍生物中都能观察到,但在具有A/B顺式构型的异佛波醇衍生物中则没有。佛波醇衍生物中20-OH的乙酰化显著降低了对CPE的抑制作用,如12-O-、20-O-二乙酰佛波醇13-癸酸酯(6a)(IC100 = 15.6 μg/ml)与化合物6(IC100 = 0.0076 μg/ml)相比,以及12-O-十四烷酰佛波醇13,20-二乙酸酯(8a)(IC100 = 15.6 μg/ml)与12-O-十四烷酰佛波醇13-乙酸酯(8)(IC100 = 0.00048 μg/ml)相比,但12-O-癸酰佛波醇13-(2-甲基丁酸酯)(4)和佛波醇12,13-二乙酸酯(9c)除外。C-3位羰基的还原会突然降低对CPE的抑制作用,如3β-羟基佛波醇12,13,20-三乙酸酯(9f)(IC100 = 500 μg/ml)与佛波醇12,13,20-三乙酸酯(9d)(IC100 = 62.5 μg/ml)相比。尽管8在抑制CPE和激活PKC方面具有同等效力,但20-OH的乙酰化和4-OH的甲基化(分别如8a和4-O-甲基-12-O-十四烷酰佛波醇13,20-二乙酸酯(8b))都会使这两种活性突然降低。另一方面,其位置异构体(12-O-乙酰佛波醇13-十四烷酸酯(8c))则没有这两种活性。8中长链酰基的去除导致这两种活性大幅丧失,如佛波醇13-乙酸酯(9b)所示。在12-O-乙酰-13-O-酰基佛波醇衍生物中,对CPE抑制作用最强的是6,其C-13位有一个十二烷酰基残基。脂肪酸碳链数量的增加和减少都会导致对CPE抑制作用的显著降低。